Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

electroCore to Present at the HC Wainwright Virtual 22nd Annual Global Investment Conference

September 11, 2020 at 8:00 AM EDT

BASKING RIDGE, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held from September 14-16, 2020.

Presentation details:

Date: Wednesday, September 16, 2020
Time: 1:30-1:50pm EDT

A live webcast of the presentation will be available on the Investors section of the company's website:

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit:

Hans Vitzthum
LifeSci Advisors


Media Contact:
Jackie Dorsky